Alpha Tau Medical (DRTS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.27B and a free-cash-flow yield of -3.0%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 2.5/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Leading · +274.6% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-33.6%
How far the last close sits under the highest price of the past five years.
Market cap
$1.27B
Trailing P/E
—
Price / book
28.6
Price / sales
—
FCF yield
-3.0%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
1.2
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
DRTS earnings
Next report: Nov 19, 2026 (Q3 2026, EPS estimate -$0.15).
Beat the EPS estimate in 0 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 10, 2026
-$0.50
-$0.14
-257.1%
$0
Q1 2026
May 18, 2026
-$0.26
-$0.12
-116.7%
$0
Q4 2025
Mar 9, 2026
-$0.14
-$0.12
-16.7%
$0
Q3 2025
Nov 20, 2025
-$0.14
-$0.12
-16.7%
$0
DRTS analyst price target
Median target $17.00 from 5 analysts, ranging $8.00 – $30.00.
Nama's AI scorecard currently rates Alpha Tau Medical Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does DRTS report earnings?
Alpha Tau Medical's next scheduled report is on Nov 19, 2026. Analysts expect EPS of -$0.15.
What is the DRTS price target?
The median analyst price target from 5 analysts is $17.00, with a range of $8.00 – $30.00.
Is DRTS Shariah compliant?
Nama's AAOIFI-style screen reads Alpha Tau Medical as Can't Tell. A figure the screen needs is missing, so it can't tell.